No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.9x · 10Y median 1.9x · 11th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:05:29.214Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:05:29.214Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:05:29.214Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:05:29.214Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:05:29.214Z. Latest historical point 2024-08-09.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:05:29.214Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:05:29.214Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:05:29.214Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for AirSculpt Technologies, Inc. (AIRS) stock was $2.00 as of Oct 6, 2026, 10:04 AM EDT, up 4.71% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -75.2% · 3-year avg -34.7%/yr
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States, Canada, and the United Kingdom. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.
Medical - Care Facilities · Tampa, FL
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.03
Revenue Est.
$34.36M
Last Quarter Results
EPS
$0.01
vs Estimate
$0.02
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AIRS | $141.09M | $2.00 | +4.71% | -75.16% | N/A | N/A | N/A |
| 2FBIOP | $141.70M | $18.00 | -0.55% | +144.21% | +0.05% | N/A | vs AIRS |
| 3FRNM | $138.67M | $17.00 | +1.01% | N/A | N/A | N/A | vs AIRS |
| 4ACOG | $146.30M | $9.42 | +2.95% | +22.21% | N/A | N/A | vs AIRS |
| 5IMRX | $146.48M | $4.04 | -0.12% | -33.09% | -32.77% | N/A | vs AIRS |
| 6KRSA | $146.51M | $31.30 | +1.88% | +75.07% | -40.41% | N/A | vs AIRS |
forward FY estimate
N/A
$42.90M
vs Estimate
$44.14M
Consensus Rating
Based on 2 analysts
Average Price Target
$4.50
+125.0% upside
Low
$3.00
Current
$2.00
High
$6.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Quarter ending Dec 2026 | $-0.03 | $-0.03 | $-0.02 | 1 |
| Quarter ending Mar 2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Quarter ending Jun 2027 | $0.00 | $0.01 | $0.01 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| FY 2027 | $-0.05 | $-0.04 | $-0.04 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $34.23M | $34.36M | $34.52M | 2 |
| Quarter ending Dec 2026 | $34.25M | $34.38M | $34.54M | 3 |
| Quarter ending Mar 2027 | $40.10M | $40.24M | $40.44M | 1 |
| Quarter ending Jun 2027 | $43.93M | $44.10M | $44.31M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $150.22M | $151.06M | $151.84M | 2 |
| FY 2027 | $154.25M | $155.11M | $155.91M | 2 |
